See more : Magic Empire Global Limited (MEGL) Income Statement Analysis – Financial Results
Complete financial analysis of CorMedix Inc. (CRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CorMedix Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kiri Industries Limited (KIRIINDUS.NS) Income Statement Analysis – Financial Results
- Northern Shield Resources Inc. (NRN.V) Income Statement Analysis – Financial Results
- PT PINAGO UTAMA Tbk (PNGO.JK) Income Statement Analysis – Financial Results
- Kuo Yang Construction Co.,Ltd (2505.TW) Income Statement Analysis – Financial Results
- Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS) Income Statement Analysis – Financial Results
CorMedix Inc. (CRMD)
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 65.41K | 190.94K | 239.23K | 283.27K | 429.80K | 329.33K | 224.11K | 210.13K | 189.27K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 205.56K | 3.73K | 148.94K | 204.85K | 373.23K | 396.79K | 114.96K | 366.67K | 318.72K | 445.80K | 201.61K | 0.00 | 0.00 | 0.00 | 0.00 | 1.04M |
| Gross Profit | -205.56K | 61.67K | 42.00K | 34.39K | -89.97K | 33.01K | 214.36K | -142.57K | -108.59K | -256.53K | -199.60K | 0.00 | 0.00 | 0.00 | 0.00 | -1.04M |
| Gross Profit Ratio | 0.00% | 94.29% | 22.00% | 14.37% | -31.76% | 7.68% | 65.09% | -63.62% | -51.68% | -135.53% | -9,975.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.16M | 10.68M | 13.13M | 13.38M | 11.05M | 18.82M | 24.49M | 15.74M | 6.28M | 1.32M | 1.23M | 1.19M | 4.10M | 5.49M | 4.89M | 3.08M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.07M | 8.65M | 8.88M | 10.26M | 7.33M | 3.49M | 1.86M | 3.15M | 3.01M | 1.17M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.80M | 20.01M | 16.35M | 13.88M | 9.87M | 8.07M | 8.65M | 8.88M | 10.26M | 7.33M | 3.49M | 1.86M | 3.15M | 3.01M | 1.17M | 691.89K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.96M | 30.69M | 29.48M | 27.26M | 20.92M | 26.90M | 33.14M | 24.62M | 16.55M | 8.65M | 4.72M | 3.04M | 7.25M | 8.51M | 6.06M | 3.77M |
| Cost & Expenses | 48.96M | 30.69M | 29.48M | 27.46M | 21.29M | 27.29M | 33.25M | 24.99M | 16.86M | 9.09M | 4.92M | 3.04M | 7.25M | 8.51M | 6.06M | 4.82M |
| Interest Income | 0.00 | 326.02K | 14.40K | 116.07K | 322.67K | 36.62K | 110.71K | 126.77K | 60.39K | 2.71K | 668.00 | 1.97K | 12.04K | 23.44K | 2.13K | 25.90K |
| Interest Expense | 0.00 | 26.52K | 15.94K | 33.23K | 787.49K | 1.87K | 5.62K | 1.31K | 3.96K | 2.09K | 1.44M | 382.94K | 12.04K | 3.09M | 2.07M | 4.21M |
| Depreciation & Amortization | 70.76K | 209.04K | 177.02K | 143.49K | 73.29K | 74.22K | 36.89K | 25.60K | 15.08K | 15.07K | 5.16K | 7.02K | 12.25K | 12.17K | 9.95K | 1.04M |
| EBITDA | -48.89M | -30.05M | -29.38M | -27.02M | -20.63M | -26.75M | -32.97M | -24.62M | -18.17M | -20.44M | -7.68M | -3.04M | -7.19M | -8.47M | -6.04M | -3.75M |
| EBITDA Ratio | 0.00% | -46,321.48% | -15,421.12% | -11,329.92% | -7,302.40% | -6,241.92% | -9,963.77% | -10,980.81% | -7,889.64% | -4,693.90% | -245,581.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -48.96M | -30.62M | -29.44M | -27.22M | -21.01M | -26.86M | -32.92M | -24.76M | -16.65M | -8.90M | -4.92M | -3.04M | -7.25M | -8.51M | -6.06M | -4.82M |
| Operating Income Ratio | 0.00% | -46,819.91% | -15,417.51% | -11,378.44% | -7,416.31% | -6,250.44% | -9,997.39% | -11,048.80% | -7,925.56% | -4,703.30% | -245,646.93% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.62M | 336.65K | -22.83K | 23.67K | -485.98K | 34.57K | -85.80K | 117.29K | -1.53M | -11.55M | -4.22M | -380.97K | 41.86K | -2.68M | -2.07M | -4.18M |
| Income Before Tax | -46.34M | -30.29M | -29.46M | -27.20M | -21.49M | -26.83M | -33.01M | -24.64M | -18.19M | -20.45M | -9.13M | -3.43M | -7.21M | -11.19M | -8.12M | -9.00M |
| Income Before Tax Ratio | 0.00% | -46,305.23% | -15,429.47% | -11,368.54% | -7,587.87% | -6,242.40% | -10,023.45% | -10,996.46% | -8,655.37% | -10,806.25% | -456,426.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -585.62K | -1.25M | -5.17M | -5.06M | 36.44K | -31.27K | 1.31K | 3.96K | 2.09K | 1.44M | 1.97K | -493.86K | -280.92K | 2.13K | 0.00 |
| Net Income | -46.34M | -29.70M | -28.21M | -22.03M | -16.43M | -26.83M | -33.01M | -24.64M | -18.19M | -20.45M | -9.13M | -3.43M | -6.71M | -10.91M | -8.12M | -9.00M |
| Net Income Ratio | 0.00% | -45,409.90% | -14,774.70% | -9,207.70% | -5,801.29% | -6,242.40% | -10,023.45% | -10,996.46% | -8,655.37% | -10,806.25% | -456,426.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.91 | -0.74 | -0.75 | -0.77 | -0.68 | -1.51 | -2.99 | -3.25 | -2.90 | -4.77 | -3.30 | -1.50 | -2.94 | -5.76 | -47.40 | -3.94 |
| EPS Diluted | -0.91 | -0.74 | -0.75 | -0.77 | -0.68 | -1.51 | -2.99 | -3.25 | -2.90 | -4.77 | -3.30 | -1.50 | -2.94 | -5.76 | -47.40 | -3.94 |
| Weighted Avg Shares Out | 50.90M | 40.14M | 37.61M | 28.56M | 24.15M | 17.82M | 11.03M | 7.59M | 6.27M | 4.29M | 2.76M | 2.28M | 2.28M | 1.89M | 171.33K | 2.28M |
| Weighted Avg Shares Out (Dil) | 50.90M | 40.27M | 37.67M | 28.56M | 24.15M | 17.82M | 11.03M | 7.59M | 6.27M | 4.29M | 2.76M | 2.28M | 2.28M | 1.89M | 171.33K | 2.28M |
CorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that it intends to offer...
CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath
BERKELEY HEIGHTS, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the resubmission of the...
Cormedix Inc. Announces Strategic Initiative With Boston Medical Center to Reduce Health Disparities in Patients at Risk for Bloodstream Infections
BERKELEY HEIGHTS, N.J. , June 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced its first-of-kind strategic initiative...
Cormedix Inc. To Present At The Jefferies Healthcare Conference
BERKELEY HEIGHTS, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be presenting...
CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath
BERKELEY HEIGHTS, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the New Drug Application...
CorMedix Inc. (CRMD) Q1 2023 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q1 2023 Earnings Call May 15, 2023 4:30 PM ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Phoebe Mounts - Executive Vice President and General...
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating...
CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath
BERKELEY HEIGHTS, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the United States Patent...
7 Small-Cap Biotech Stocks with Massive Potential
While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappointments or outright failures, these speculative enterprises are obviously less funded.
Here's Why CorMedix (CRMD) Looks Ripe for Bottom Fishing
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the...
Source: https://incomestatements.info
Category: Stock Reports